Drug Profile


Alternative Names: Amlodipine/hydrochlorothiazide/telmisartan; Hydrochlorothiazide/amlodipine/telmisartan; Hydrochlorothiazide/telmisartan/amlodipine; Telmisartan/amlodipine/hydrochlorothiazide; Telmisartan/hydrochlorothiazide/amlodipine

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypertension

Most Recent Events

  • 07 Jan 2016 Preregistration for Hypertension in Japan before January 2016 (PO)
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/hydrochlorothiazide (Micardis® family) in Japan
  • 01 Oct 2014 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Japan (NCT02183675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top